NCT07884058Not yet recruitingPhase 2
IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
Randomized, Double-Blind, Placebo-controlled Trial Of IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This clinical trial will investigate the effect of standardized Irvingia gabonensis extract (IGOB131) on GLP-1 dynamics, DPP-4 activity, metabolic parameters, and inflammatory markers in adults with obesity. The study will compare IGOB131 to a placebo to find out if it exerts any significant metabolic benefits through GLP-1 and DPP-4 modulation, and the reduction of adiposity and systemic inflammation. Participants will: Take IGOB131 or a placebo every day for 16 weeks Visit the clinic once every 4 weeks for checkups and tests
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 2 Oct 2026
- Start date
- Dec 2026
- Primary completion date
- Oct 2027
- Lead sponsor
- University of Yaounde 1
- Diseases
- Obesity
- NCT number
- NCT07884058
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From Dec 2026 to the primary completion date, Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any medication or natural health product that might affect the parameters of interest in this study
Other illness
- Diabetes mellitus requiring daily insulin management
- Active infection
- Systemic diseases, including HIV/AIDS, Active hepatitis, Clinical signs of active malignancy within the past 5 years
Age
- Participants younger than 18 years or older than 65 years
Other
- Participants not available for the study period
- Morbid obesity (BMI \> 34.9 kg/m²)
- Pregnancy or breastfeeding
Who the study is looking for
- Males and females with BMI between 25 and 34 kg/m²
- Participants aged 18 to 65 years old
- Participants willing to comply with the study protocol
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.